MODALIS THERAPEUTICS CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 77 JPY | 0.00% |
|
-1.28% | -37.90% |
| Apr. 15 | Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs | MT |
| Feb. 23 | Modalis Therapeutics to Reduce Stated Capital and Capital Reserves | MT |
| Sales 2022 | 40M 256K | Sales 2023 | - | Capitalization | 3.92B 25.01M |
|---|---|---|---|---|---|
| Net income 2022 | -2.7B -17.26M | Net income 2023 | -2.39B -15.27M | EV / Sales 2022 | 171 x |
| Net cash position 2022 | 2.93B 18.74M | Net cash position 2023 | 1.47B 9.4M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-3.61
x | P/E ratio 2023 |
-1.61
x | Employees | 37 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 83.39% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -1.28% | ||
| Current month | -19.79% | ||
| 1 month | -16.30% | ||
| 3 months | -32.46% | ||
| 6 months | -42.96% | ||
| Current year | -37.90% |
1 week
77.00
81.00
1 month
77.00114.00
Current year
77.00126.00
1 year
77.00336.00
3 years
77.001 929.00
5 years
77.004 070.00
10 years
77.004 070.00
| Managers | Title | Age | Since |
|---|---|---|---|
Haru Morita
FOU | Founder | 54 | 15-12-31 |
Naoki Kobayashi
DFI | Director of Finance/CFO | 60 | - |
Tetsuya Yamagata
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joseph McCracken
BRD | Director/Board Member | 70 | 18-07-31 |
Toshio Furuta
BRD | Director/Board Member | 62 | 18-11-30 |
Haru Morita
FOU | Founder | 54 | 15-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 77 | 0.00% | 147 800 |
| 24-04-25 | 77 | 0.00% | 89,000 |
| 24-04-24 | 77 | 0.00% | 164,600 |
| 24-04-23 | 77 | -2.53% | 499,500 |
| 24-04-22 | 79 | +1.28% | 191,100 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT
More quotes
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
Calendar
2024-05-07
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -37.90% | 16.93M | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.61% | 22.02B | |
| -17.84% | 20.9B | |
| -10.63% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- 4883 Stock
